Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25300447 | 1.00 | LMNA (0.45) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL2432723 | 0.79 | MAOB (0.53) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL2010000 | 0.79 | MAOA (0.62) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL17724009 | 0.77 | MAOA (0.51) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL2896177 | 0.76 | CA12 (0.47) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL12988092 | 0.76 | NPC1 (0.53) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL6237938 | 0.76 | DAO (0.48) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL2198159 | 0.76 | CHRNA7 (0.49) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL12017478 | 0.75 | GPR35 (0.49) | LMNARECQLKMT2ANPC1RAB9A | |
| SCHEMBL5600370 | 0.75 | LMNA (0.44) | LMNARECQLKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| CN-119343340-A | Methods of preparing modified BTK inhibitors | 普林斯匹亚生物制药公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024213089-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海壹迪生物技术有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4213832-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022152229-A1 | CLASS OF MORPHOLINE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-07-21 | — | — | WO | disclosed |
| US-20220112194-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| WO-2022060764-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | LMNA 4569/4885RECQL 3620/4885KMT2A 655/4885 |
| US-20220112194-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | LMNA 2624/4885RECQL 2411/4885KMT2A 69/4885 |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | LMNA 1470/4885RECQL 1952/4885KMT2A 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.